Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Joyce

Physical Medicine & Rehabilitation Portland, OR Medical Doctor

NPI 1194136036 CMS profile 5701476

5050 Ne Hoyt St Ste 611, Portland, OR 97213

Open in the dashboard

General payments

$2,163

31 records reported · program years 2019–2025

Research payments

$16

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Joyce of Portland, OR is reported in the CMS Open Payments database as having received $2,163 across 31 general payments and $16 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18 1
2024 General $27 1
2023 General $425 9
2022 General $1,194 14
2021 General $181 2
2021 Research $16 1
2019 General $319 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Joyce
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Andrew Joyce were reported at $18. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Andrew Joyce Physical Medicine & Rehabilitation median Middle half National median
2019 $319 $133 $45–$390 $163
2020 $0 $88 $29–$272 $114
2021 $181 $116 $33–$360 $132
2022 $1,194 $123 $40–$378 $149
2023 $425 $131 $43–$396 $160
2024 $27 $141 $45–$409 $164
2025 $18 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,069 13 payments
  2. Abbott Laboratories $306 5 payments
  3. Nevro Corp. $286 3 payments
  4. SPR Therapeutics, Inc $181 2 payments
  5. Ipsen Biopharmaceuticals, Inc $113 5 payments
  6. Boston Scientific Corporation $107 1 payment
  7. Relievant Medsystems, Inc. $55 1 payment
  8. Averitas Pharma Inc. $46 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,272 24 payments
  2. Travel and Lodging $891 7 payments
Products named General payments · program years 2019–2025
  1. KYPHON EXPRESS II KYPHOPAK TRAY $1,030 11 payments
  2. SPRINT PNS System $181 2 payments
  3. Senza $178 2 payments
  4. S-Series SCS Leads $117 1 payment
  5. DYSPORT $113 5 payments
  6. Senza Spinal Cord Stimulation System $109 1 payment
  7. WaveWriter Alpha Prime 16 $107 1 payment
  8. Proclaim Family of SCS IPGs $94 2 payments
  9. PROCLAIM $69 1 payment
  10. Intracept $55 1 payment
  11. Other $167 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $16 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

251

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$2,967

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

0%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 72 $1,245
Tizanidine Hcl Generic 76 $771
Duloxetine Hcl Generic 49 $582
Meloxicam Generic 29 $177
Gabapentin Generic 11 $129
Diazepam Generic 14 $64

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$60,288

Of which drugs: $98

Medicare patients

237

Average age 72

Services billed

1,403

156 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 66%
Depression 32%
Diabetes 30%
Osteoporosis 24%
Chronic kidney disease 22%
Ischemic heart disease 19%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 35 126 $89
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 14 517 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record